Evolution of living donor liver transplantation over 10 years: experience of a single center
- PMID: 18751944
- DOI: 10.1007/s00595-007-3729-8
Evolution of living donor liver transplantation over 10 years: experience of a single center
Abstract
Purpose: To evaluate the changes in living donor liver transplantations (LDLTs) over the last 10 years, we analyzed our experience of performing LDLT in a single center.
Methods: We performed 73 LDLTs over the 10 years between 1997 and 2007 in Nagasaki University Hospital, Japan.
Results: Initially, from 1997 to 2003, LDLT was performed for pediatric patients; then, between 2004 and 2007, adult-to-adult LDLT was introduced, primarily for hepatocellular carcinoma (HCC) in liver cirrhosis. We also began performing LDLTs for adults with ABO-incompatible blood type combination in the latter period. As the number of adult-to-adult LDLTs increased, left-sided grafts became fi rst choice for these patients. Survival rates were 88.3%, 77.2%, 70.2% at 1, 3, and 5 years, respectively. There was a relatively low incidence of arterial complications, and although the incidence of biliary complications was high initially, it decreased with experience. Likewise, the operative time, blood loss, and hospital stay after LDLT also improved remarkably.
Conclusion: Over the last 10 years the indications for, and operative techniques used in LDLT have changed dramatically, even in a single center in Japan.
Similar articles
-
Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.J Hepatol. 2018 Jun;68(6):1153-1162. doi: 10.1016/j.jhep.2018.02.002. Epub 2018 Feb 13. J Hepatol. 2018. PMID: 29452208
-
ABO-incompatible Living Donor Liver Transplantation With Rituximab and Total Plasma Exchange Does Not Increase Hepatocellular Carcinoma Recurrence.Transplantation. 2018 Oct;102(10):1695-1701. doi: 10.1097/TP.0000000000002154. Transplantation. 2018. PMID: 29494419
-
Impact of ABO-incompatibility on hepatocellular carcinoma recurrence after living donor liver transplantation.Eur J Surg Oncol. 2019 Feb;45(2):180-186. doi: 10.1016/j.ejso.2018.07.066. Epub 2018 Sep 14. Eur J Surg Oncol. 2019. PMID: 30243467
-
Living-donor liver transplantation: present status and future perspective.J Med Invest. 2005 Feb;52(1-2):22-32. doi: 10.2152/jmi.52.22. J Med Invest. 2005. PMID: 15751270 Review.
-
Liver transplantation for hepatocellular carcinoma: Korean experience.J Hepatobiliary Pancreat Sci. 2010 Sep;17(5):539-47. doi: 10.1007/s00534-009-0167-6. Epub 2009 Sep 2. J Hepatobiliary Pancreat Sci. 2010. PMID: 19727542 Review.
Cited by
-
Evolution of Liver Transplantation Over the Last 2 Decades Based on a Single-Center Experience of 300 Cases.Ann Transplant. 2023 Nov 14;28:e941796. doi: 10.12659/AOT.941796. Ann Transplant. 2023. PMID: 37957951 Free PMC article.
-
Lack of grafted liver rejuvenation in adult-to-pediatric liver transplantation.Dig Dis Sci. 2011 May;56(5):1542-7. doi: 10.1007/s10620-010-1445-5. Epub 2010 Oct 9. Dig Dis Sci. 2011. PMID: 20936349
-
Model for end-stage liver disease versus the Child-Pugh score in predicting the post-transplant 3-month and 1-year mortality in a cohort of Chinese recipients.Surg Today. 2010;40(1):38-45. doi: 10.1007/s00595-009-4114-6. Epub 2009 Dec 29. Surg Today. 2010. PMID: 20037838
-
Outcomes of patients with benign liver diseases undergoing living donor versus deceased donor liver transplantation.PLoS One. 2011;6(11):e27366. doi: 10.1371/journal.pone.0027366. Epub 2011 Nov 7. PLoS One. 2011. PMID: 22087299 Free PMC article.
-
Association Between Trough Level of Tacrolimus and Change in Estimated Glomerular Filtration Rate 1 Year After Living Donor Liver Transplantation.Ann Transplant. 2021 Feb 9;26:e928858. doi: 10.12659/AOT.928858. Ann Transplant. 2021. PMID: 33558451 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials